These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22727040)

  • 1. Role of prostaglandin D2 and the autonomic nervous system in niacin-induced flushing.
    Parson HK; Harati H; Cooper D; Vinik AI
    J Diabetes; 2013 Mar; 5(1):59-67. PubMed ID: 22727040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms.
    Dishy V; Liu F; Ebel DL; Atiee GJ; Royalty J; Reilley S; Paolini JF; Wagner JA; Lai E
    J Clin Pharmacol; 2009 Apr; 49(4):416-22. PubMed ID: 19246721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients' experiences of niacin-induced flushing in clinical practice: a structured telephone interview.
    Kamal-Bahl S; Watson DJ; Ambegaonkar BM
    Clin Ther; 2009 Jan; 31(1):130-40. PubMed ID: 19243714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aspirin on niacin-induced cutaneous reactions.
    Whelan AM; Price SO; Fowler SF; Hainer BL
    J Fam Pract; 1992 Feb; 34(2):165-8. PubMed ID: 1737967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
    Kawata AK; Revicki DA; Thakkar R; Jiang P; Krause S; Davidson MH; Punzi HA; Padley RJ
    Clin Drug Investig; 2009; 29(4):215-29. PubMed ID: 19301936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
    Maccubbin D; Koren MJ; Davidson M; Gavish D; Pasternak RC; Macdonell G; Mallick M; Sisk CM; Paolini JF; Mitchel Y
    Am J Cardiol; 2009 Jul; 104(1):74-81. PubMed ID: 19576324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions.
    Jungnickel PW; Maloley PA; Vander Tuin EL; Peddicord TE; Campbell JR
    J Gen Intern Med; 1997 Oct; 12(10):591-6. PubMed ID: 9346454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved control of niacin-induced flushing using an optimized once-daily, extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; Shamp TR
    Int J Clin Pharmacol Ther; 2006 Dec; 44(12):633-40. PubMed ID: 17190373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model.
    Papaliodis D; Boucher W; Kempuraj D; Michaelian M; Wolfberg A; House M; Theoharides TC
    J Pharmacol Exp Ther; 2008 Dec; 327(3):665-72. PubMed ID: 18784348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niacin skin flush test: a research tool for studying schizophrenia.
    Nadalin S; Buretić-Tomljanović A; Rubesa G; Tomljanović D; Gudelj L
    Psychiatr Danub; 2010 Mar; 22(1):14-27. PubMed ID: 20305586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
    Paolini JF; Mitchel YB; Reyes R; Kher U; Lai E; Watson DJ; Norquist JM; Meehan AG; Bays HE; Davidson M; Ballantyne CM
    Am J Cardiol; 2008 Mar; 101(5):625-30. PubMed ID: 18308010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin reduces cutaneous flushing after administration of an optimized extended-release niacin formulation.
    Cefali EA; Simmons PD; Stanek EJ; McGovern ME; Kissling CJ
    Int J Clin Pharmacol Ther; 2007 Feb; 45(2):78-88. PubMed ID: 17323787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apple pectin for the reduction of niacin-induced flushing.
    Moriarty PM; Backes J; Dutton JA; He J; Ruisinger JF; Schmelzle K
    J Clin Lipidol; 2013; 7(2):140-6. PubMed ID: 23415433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Niacin use and cutaneous flushing: mechanisms and strategies for prevention.
    Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):14B-19B. PubMed ID: 18375236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of different aspirin regimens for reduction of niacin-induced flushing.
    Banka SS; Thachil R; Levine A; Lin H; Kaafarani H; Lee J
    Am J Health Syst Pharm; 2017 Jun; 74(12):898-903. PubMed ID: 28432049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.
    Jacobson TA
    Mayo Clin Proc; 2010 Apr; 85(4):365-79. PubMed ID: 20360295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1.
    Lai E; De Lepeleire I; Crumley TM; Liu F; Wenning LA; Michiels N; Vets E; O'Neill G; Wagner JA; Gottesdiener K
    Clin Pharmacol Ther; 2007 Jun; 81(6):849-57. PubMed ID: 17392721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.
    Rhodes T; Norquist JM; Sisk CM; McQuarrie K; Trovato A; Liao J; Miller T; Maccubbin D; Watson DJ
    Int J Clin Pract; 2013 Dec; 67(12):1238-46. PubMed ID: 24102896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush.
    Meyers CD; Liu P; Kamanna VS; Kashyap ML
    Atherosclerosis; 2007 Jun; 192(2):253-8. PubMed ID: 16945375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.